Immuneering (NASDAQ:IMRX) Releases Earnings Results, Misses Estimates By $0.16 EPS

Immuneering (NASDAQ:IMRX) issued its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16), Zacks reports.

Immuneering Stock Performance

Shares of IMRX opened at $1.65 on Friday. The stock’s 50-day simple moving average is $1.80 and its 200 day simple moving average is $1.98. Immuneering has a 52-week low of $1.00 and a 52-week high of $3.83. The stock has a market capitalization of $51.23 million, a price-to-earnings ratio of -0.84 and a beta of -0.32.

Analyst Ratings Changes

Several brokerages have issued reports on IMRX. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Chardan Capital reiterated a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 target price on shares of Immuneering in a research note on Thursday, February 6th.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.